Healthcare Industry News: Stent-Graft
News Release - April 22, 2009
Bolton Medical Obtains CE Mark for the New RELAY Plus Thoracic Stent-Graft Delivery SystemSUNRISE, FL--(Healthcare Sales & Marketing Network)--Apr 22, 2009 -- At the recent Charing Cross Symposium in London, Bolton Medical announced the launch of a new and further improved delivery system: RELAY Plus. The new delivery system is designed for use with the highly successful RELAY Thoracic Stent-Graft and offers some key new features:
-- Longer 60cm braided outer sheath with enhanced radiopacity and reinforced pushrod provides improved push ability and visibility in challenging aortic anatomies
-- New nitinol inner catheter provides improved self alignment of the dual sheath system
RELAY Plus was CE marked in March 2009 and is available in Europe and all countries that recognize CE mark certification. It will be marketed along with the RELAY Thoracic Stent-Graft which was launched in Europe in 2005 and is well underway in clinical trials in the US.
RELAY and RELAY NBS Endovascular Stent-Grafts are indicated for the treatment of main thoracic aortic pathologies such as aneurysms, dissections, penetrating ulcers, pseudoaneurysms and intramural haematoma in adult patients. It is expected that by the end of 2009 more than 3000 RELAY and RELAY NBS Stent Grafts will have been implanted worldwide.
Thoracic Stent-Grafts are an option to traditional open surgery for patients requiring treatment for main thoracic pathologies. The endovascular Stent-Graft procedure generally results in a reduced hospital stay and a shorter recovery time for patients. This can provide a considerable advantage in care given that the majority of patients who require this treatment are seniors.
Bolton Medical is a private company with European operations based in Barcelona, Spain and US operations in Sunrise, Florida. Bolton Medical is wholly owned subsidiary of Werfen Life Group, a diverse manufacturer and supplier of products for the medical industry.
Source: Bolton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.